Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study

Uemura, Osamu; Honda, Masashi; Matsuyama, Tomohiro; Ishikura, Kenji; Hataya, Hiroshi; Yata, Nahoko; Nagai, Takuhito; Ikezumi, Yohei; Fujita, Naoya; Ito, Shuichi; Iijima, Kazumoto; Kitagawa, Teruo

doi:10.1007/s10157-011-0452-y

Cited by 102 publications

(63 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Until recently, this value was still widely used in clinical work to assess kidney function. Our study showed that creatinine value increased gradually with age, a finding matched by those of Uemura et al (2011), who reported that serum creatinine concentrations in Japanese children differ significantly according to gender and age.…”

Section: Discussionsupporting

confidence: 72%

Relationship between serum creatinine and obesity in children in Xinjiang, China

Xie

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT.This study was designed to analyze the relationship between serum creatinine and body mass index in children in Xinjiang, China. We used a stratified sampling method to select 5222 children aged 6-17 years in 3 areas in Xinjiang and then measured serum creatinine with an enzymatic method. Our analysis showed that the mean serum creatinine of the various age groups differed, and the reference value increased gradually with age. In the groups with subjects older than 10 years, the serum creatinine values had a positive correlation with body mass index (r = 0.016, 10-and 11-year-olds; r = 0.177, 12-and 13-yearolds; r = 0.314, 14-and 15-year-olds; r = 0.380, 16-and 17-year-olds; P < 0.05). In the multivariate regression analysis model, the positive relationship existed even after we removed influencing factors such as blood sugar and cholesterol (β = 0.041, 10-and 11-year-olds; β = 0.081, 12-and 13-year-olds; β = 0.183, 14-and 15-year-olds; β = 0.171, 16-and 17-year-olds; P < 0.05). Obesity is an independent risk factor associated with increasing serum creatinine levels in children aged more than 10 years. Weight control is important in the protection of renal function.

show abstract

Section: Discussionsupporting

confidence: 72%

Relationship between serum creatinine and obesity in children in Xinjiang, China

Xie

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…The Japanese Society of Nephrology has issued precautions for use of eculizumab in patients with secondary TMA [21], which is classified according to underlying conditions or CACs [10,22]. Findings from a retrospective study suggest that the benefits of eculizumab vary in relation to the underlying condition of secondary aHUS [22].…”

Section: Discussionmentioning

confidence: 99%

“…MAHA was defined as a hemoglobin level of < 10 g/dL and thrombocytopenia as a platelet count (PLT) of < 15 × 10 4 /µL. AKI in children was defined as a serum creatinine level at least 1.5 times the upper limit of the age-and sex-specific pediatric reference range [10]. The approved eculizumab dosing is based on the patient's weight (Supplementary Table 1) [7].…”

Section: Study Design and Patientsmentioning

confidence: 99%

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background In 2013, eculizumab was approved for treatment of the atypical hemolytic-uremic syndrome (aHUS) in Japan, which was defined as a thrombotic microangiopathy (TMA) excluding Shiga toxin-producing Escherichia coli-HUS and thrombotic thrombocytopenic purpura. Simultaneously, post-marketing surveillance was started to assess its safety and effectiveness. In 2016, Japanese clinical guide redefined terms to limit the use of "aHUS" to complement-mediated HUS only. Accordingly, TMA with other causes was defined as secondary TMA. Here we report the interim analysis of post-marketing surveillance of pediatric patients with aHUS and secondary TMA. Methods Pediatric patients treated with eculizumab from approval to 15 March 2017 were included in this observational real-world study. Clinical endpoints of effectiveness were TMA event-free status, complete TMA response, platelet count normalization, and improvement of estimated glomerular filtration rate (eGFR). Adverse reactions to eculizumab were also analyzed. Results In 27 pediatric patients with aHUS, median age at diagnosis was 4 years. Complement genes' variants were detected in 14 of 21 patients (66.7%). Median time from diagnosis to eculizumab initiation was 2.0 days. TMA event-free status, complete TMA response, platelet normalization, and improvement in eGFR were achieved in 85.2, 36.4, 78.3, and 75.0% of patients, respectively. Three patients with aHUS died. Twenty-four and 10 adverse reactions were reported in 31 aHUS patients and 17 secondary TMA patients, respectively; however, no eculizumab-related death or meningococcal infection was reported. Conclusions This interim analysis confirmed that eculizumab is well-tolerated and effective for Japanese pediatric patients with aHUS in a real-world setting.

show abstract

“…Regarding reference values, the PELOD (Performance of the Pediatric Logistic Organ Dysfunction)‐2 (Table 7(a))465 scoring system is widely used in international clinical research as an index of pediatric organ dysfunction, and do not necessarily match with the age‐specific reference values proposed in Japan (Table 7). 466 Because the serum creatinine value depends on the muscle mass, particularly in post‐pubescent patients, large gaps can arise between different genders and ethnicities, and may also result from differences in measuring methods (e.g., Jaffe method, enzyme method, etc. ), and validation will be necessary here as well.…”

Section: Cq19: Pediatric Considerationsmentioning

confidence: 99%

The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J‐SSCG2016)

Nishida

Ogura

Egi

et al. 2018

Acute Medicine & Surgery

157

View full text Add to dashboard Cite

Background and PurposeThe Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J‐SSCG 2016), a Japanese‐specific set of clinical practice guidelines for sepsis and septic shock created jointly by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine, was first released in February 2017 in Japanese. An English‐language version of these guidelines was created based on the contents of the original Japanese‐language version.MethodsMembers of the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine were selected and organized into 19 committee members and 52 working group members. The guidelines were prepared in accordance with the Medical Information Network Distribution Service (Minds) creation procedures. The Academic Guidelines Promotion Team was organized to oversee and provide academic support to the respective activities allocated to each Guideline Creation Team. To improve quality assurance and workflow transparency, a mutual peer review system was established, and discussions within each team were open to the public. Public comments were collected once after the initial formulation of a clinical question (CQ), and twice during the review of the final draft. Recommendations were determined to have been adopted after obtaining support from a two‐thirds (>66.6%) majority vote of each of the 19 committee members.ResultsA total of 87 CQs were selected among 19 clinical areas, including pediatric topics and several other important areas not covered in the first edition of the Japanese guidelines (J‐SSCG 2012). The approval rate obtained through committee voting, in addition to ratings of the strengths of the recommendation and its supporting evidence were also added to each recommendation statement. We conducted meta‐analyses for 29 CQs. Thirty seven CQs contained recommendations in the form of an expert consensus due to insufficient evidence. No recommendations were provided for 5 CQs.ConclusionsBased on the evidence gathered, we were able to formulate Japanese‐specific clinical practice guidelines that are tailored to the Japanese context in a highly transparent manner. These guidelines can easily be used not only by specialists, but also by non‐specialists, general clinicians, nurses, pharmacists, clinical engineers, and other healthcare professionals.

show abstract

Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study

Cited by 102 publications

References 9 publications

Relationship between serum creatinine and obesity in children in Xinjiang, China

Relationship between serum creatinine and obesity in children in Xinjiang, China

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance

The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J‐SSCG2016)

Contact Info

Product

Resources

About